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Abstract 
We tested the hypothesis that glucose-insulin-potassium (GIK)-induced protection against myocardial infarction 
depends on ATP-dependent K+ (KATP) channel activation and is abolished by hyperglycemia before the ischemia. 
Dogs were subjected to a 60-min coronary artery occlusion and 3-h reperfusion in the absence or presence of 
GIK (25% dextrose; 50 IU insulin/l; 80 mM/l KCl infused at 1.5 ml·kg−1·h−1) beginning 75 min before coronary 
artery occlusion or 5 min before reperfusion. The role of KATP channels was evaluated by pretreatment with 
glyburide (0.1 mg/kg). The efficacy of GIK was investigated with increases in blood glucose (BG) concentrations 
to 300 or 600 mg/dl or experimental diabetes (alloxan/streptozotocin). Infarct size (IS) was 29 ± 2% of the area 
at risk in control experiments. GIK decreased (P < 0.05) IS when administered beginning 5 min before 
reperfusion. This protective action was independent of BG (13 ± 2 and 12 ± 2% of area at risk; BG = 80 or 600 
mg/dl, respectively) but was abolished in dogs receiving glyburide (30 ± 4%), hyperglycemia before ischemia (27 
± 4%), or diabetes (25 ± 3%). IS was unchanged by GIK when administered before ischemia independent of BG 
(31 ± 3, 27 ± 2, and 35 ± 3%; BG = 80, 300, and 600 mg/dl, respectively). The insulin component of GIK promotes 
cardioprotection by KATP channel activation. However, glucose decreases KATP channel activity, and this effect 
predominates when hyperglycemia is present before ischemia. 
in the early 1960s, glucose-insulin-potassium (GIK) was first proposed as a treatment to reduce myocardial 
ischemic injury (26). Several clinical trials conducted since that initial report have indicated that GIK may 
improve outcome in patients with acute myocardial infarction (6, 8), but the use of GIK in this setting has not 
been widely accepted. GIK may produce beneficial effects during ischemia and reperfusion by optimizing 
substrate utilization (5). Alternatively, recent data (10, 15, 16, 24) suggest that insulin may be the primary 
component of GIK responsible for cardioprotection by favorably modulating cell survival pathways independent 
of metabolic effects. Unlike other modalities that activate endogenous signal transduction pathways to produce 
myocardial protection before the onset of ischemia, insulin-induced protective effects have been shown to 
occur at reperfusion (16). 
A large body of experimental evidence accumulated over the past decade implicates ATP-regulated K+ (KATP) 
channels as central mediators of protection against reversible and irreversible ischemic injury. Activation of 
these channels is impaired by acute and chronic hyperglycemia (17, 21). Hyperglycemia is a major contributor to 
and an independent predictor of short- and long-term cardiovascular mortality in patients with and without 
diabetes mellitus (DM) (13). However, control of blood glucose (BG) concentration and the potentially 
deleterious consequences of hyperglycemia during administration of GIK have received relatively little attention. 
A study by Heng et al. (14) conducted before the advent of thrombolytic drugs demonstrated that patients with 
acute myocardial infarction who were treated with GIK suffered greater mortality than those who did not 
receive GIK. Notably, BG concentrations were very poorly controlled in the study by Heng et al. (14) and 
increased to levels as high as 600 mg/dl during the first 2 h of treatment in patients receiving GIK. A more recent 
study (22) conducted in patients undergoing off-pump coronary artery surgery demonstrated that GIK failed to 
reduce myocardial injury compared with placebo. This trial was subsequently discontinued after interim analysis 
revealed a possible increase in complication rate that may have been related to recalcitrant hyperglycemia in 
the GIK group. In the present investigation, we tested the hypothesis that GIK decreases myocardial infarct size 
(IS) in a canine model of coronary artery occlusion (CAO) when administered at reperfusion and that this 
beneficial effect requires activation of KATP channels. In addition, we tested the hypothesis that the presence of 
acute or chronic hyperglycemia before the onset of ischemia abolishes any beneficial effect afforded by GIK. 
MATERIALS AND METHODS 
All experimental procedures and protocols used in this investigation were reviewed and approved by the 
Institutional Animal Care and Use Committee of the Medical College of Wisconsin. All procedures and protocols 
conformed to the American Physiological Society “Guiding Principles in the Care and Use of Animals” and the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, 
Revised 1996). 
Acute surgical preparation. 
Implantation of instruments has been previously described (20). Briefly, barbiturate-anesthetized dogs (18–22 
kg) were ventilated using positive pressure after endotracheal intubation. Arterial blood gas tensions and acid-
base status were maintained within physiological limits by adjustment of tidal volume and respiratory rate. A 
fluid-filled catheter was inserted into the right femoral vein and artery for drug administration and withdrawal 
of reference blood flow samples, respectively. After thoracotomy was performed in the left fifth intercostal 
space, a dual micromanometer-tipped catheter was inserted into the left ventricle (LV) and ascending aorta for 
measurement of LV and arterial pressures, respectively, and the maximum rate of increase of LV pressure 
(+dP/dtmax). A 1.5- to 2-cm segment of the proximal left anterior descending coronary artery distal to the first 
diagonal branch was isolated, and a silk ligature was placed around the vessel to produce CAO and reperfusion. 
A fluid-filled catheter was inserted into the left atrium for radioactive microsphere injection. Temperature was 
maintained with a heating blanket. Hemodynamic data were continuously monitored on a polygraph and 
simultaneously digitized by using a computer interfaced with an analog-to-digital converter. 
Experimental protocol. 
All dogs were subjected to a 60-min CAO and 3 h of reperfusion (Fig. 1). Control dogs received an intravenous 
infusion of saline (1.5 ml·kg−1·h−1). The effects of GIK (25% dextrose; 50 IU insulin/l; 80 mM/l KCl infused 
intravenously at 1.5 ml·kg−1·h−1) (6) on IS were evaluated in two groups of dogs receiving GIK beginning 75 min 
before CAO (GIKCon) or 5 min before reperfusion (GIK reperfusion). Whether acute hyperglycemia modulated the 
actions of GIK was evaluated in three additional groups of dogs during infusion of 25% dextrose to increase BG 
to 300 or 600 mg/dl beginning 75 min before CAO (GIK300 or GIK600) or 5 min before reperfusion 
(GIK600 reperfusion). The impact of KATP channel activity on the protective effects of GIK was investigated in 
another group of dogs pretreated with glyburide (0.1 mg/kg, intravenously; Glb+GIK reperfusion) (20). Finally, 
the hypothesis that the presence of acute or chronic hyperglycemia abolishes the cardioprotection produced by 
GIK administered at reperfusion was examined in two separate groups of dogs, who received 25% dextrose to 
increase BG to 600 mg/dl beginning 75 min before CAO (Hyp+GIK reperfusion) or were subjected to chemically 
induced DM (DM+GIK reperfusion) (intravenous administration of 40 mg/kg alloxan and 25 mg/kg 
streptozotocin) (21). 
 
Fig. 1.Schematic illustration of the experimental protocol. GIK, glucose-insulin-potassium; GIK300, GIK given at 
300 mg/dl; GIK600, GIK given at 600 mg/dl; Glb, glyburide; Hyp, hyperglycemia; DM, diabetes mellitus; CAO, 
coronary artery occlusion; Con, saline control. 
 
Quantification of IS. 
IS was determined at the conclusion of the each experiment as previously described (29). Briefly, the LV area at 
risk (AAR) for infarction was separated from the normal area, and each region was incubated at 37°C for 20 to 30 
min in 1% 2,3,5-triphenyltetrazolium chloride in 0.1 M phosphate buffer adjusted to pH 7.4. After overnight 
storage in 10% formaldehyde, infarcted and noninfarcted myocardium within the AAR was separated and 
weighed. IS was expressed as a percentage of the AAR. 
Quantification of regional myocardial blood flow. 
Regional myocardial blood flow was measured under baseline conditions, during CAO, and after 1 h of 
reperfusion using the radioactive microsphere technique as previously described (18). Myocardial blood flow 
was calculated as Qr·Cm·Cr−1, where Qr is the rate of withdrawal of the reference blood flow sample (in 
ml/min), Cm is the activity (in cpm/g) of the myocardial tissue sample, and Cr is the activity (in cpm) of the 
reference blood flow sample. Transmural myocardial blood flow was calculated as the average of subepicardial, 
midmyocardial, and subendocardial blood flows. 
Statistical analysis. 
Statistical analysis of data within and between groups was performed using ANOVA for repeated measures, 
followed by Student-Newman-Keuls test. A P value <0.05 was considered statistically significant. All data are 
expressed as means ± SE. 
RESULTS 
Seventy-two dogs were instrumented to obtain 64 successful experiments. Four dogs were excluded from 
subsequent analysis because subendocardial collateral blood flow exceeded 0.15 ml·min−1·g−1 (one dog each in 
the GIKCon, GIK300, GIK reperfusion, and Hyp+GIK reperfusion groups). Four dogs were excluded due to intractable 
ventricular fibrillation during CAO (one each in the GIKCon, GIK600, GIK reperfusion, and Hyp+GIK reperfusion 
groups). One dog died after diabetes was chemically induced and was therefore not instrumented. 
Systemic hemodynamics. 
No differences in systemic hemodynamics were observed between groups under baseline conditions or during 
CAO and reperfusion (Table 1). Transient increases in LV +dP/dtmax were observed in dogs receiving GIK or 
dextrose alone before ischemia, but these increases were not sustained during CAO or after reperfusion. 
Table 1. Systemic hemodynamics 
  
   
Reperfusion, h  
 
 
Baseline Intervention 30-min CAO 1 2 3 
HR, beats/min 
      
    Con 132±5 127±5 124±5 121±6 128±5 124±6 
    GIKCon 141±6 135±4 134±5 127±6 136±10 133±6 
    GIK300 128±6 130±7 119±6 117±6 117±6 123±9 
    GIK600 128±4 129±4 122±4 118±4 114±8* 113±7* 
    GIK reperfusion 131±7 124±6 125±6 116±5 115±6 112±8* 
    GIK600 reperfusion 128±3 122±5 117±5 118±6 119±7 119±8 
    Glb + GIK reperfusion 129±7 122±7 127±5 123±6 120±7 123±7 
    Hyp + GIK reperfusion 134±4 132±4 133±4 128±7* 119±5* 122±6* 
    DM + GIK reperfusion 138±5 134±7 129±9 122±7* 121±7* 124±8* 
MAP, mmHg 
      
    Con 100±4 101±4 92±5 90±6 91±5 91±5 
    GIKCon 97±4 102±7 90±5 99±4 103±2 97±3 
    GIK300 93±4 95±3 75±4* 77±3* 81±6 87±2 
    GIK600 98±6 103±5 82±5* 84±5* 78±4* 74±4* 
    GIK reperfusion 92±5 96±4 86±4 97±6 99±5 95±6 
    GIK600 reperfusion 101±4 103±5 88±6* 97±7 101±6 98±6 
    Glb + GIK reperfusion 92±4 85±6 80±6 86±7 86±6 85±7 
    Hyp + GIK reperfusion 98±4 104±3 97±5 97±6 90±7 88±6 
    DM + GIK reperfusion 101±5 100±4 87±4 89±7 91±6 86±8 
LVSP, mmHg 
      
    Con 110±5 110±4 96±5 91±6 96±5 95±5 
    GIKCon 108±5 114±7 98±5 105±5 109±4 105±4 
    GIK300 105±4 105±3 82±4* 83±3* 87±6* 93±3 
    GIK600 110±6 115±7 87±5* 90±5* 84±4* 80±3* 
    GIK reperfusion 103±5 107±4 93±3 102±5 105±6 99±7 
    GIK600 reperfusion 109±3 113±4 92±6* 102±8 104±6 100±6 
    Glb + GIK reperfusion 103±5 97±6 87±6* 93±6 96±5 95±6 
    Hyp + GIK reperfusion 108±4 115±3 101±6 103±6 97±8 96±7 
    DM + GIK reperfusion 109±6 109±3 94±3 98±6 99±7 94±8 
LVEDP, mmHg 
      
    Con 5±1 5±1 16±3* 21±4* 14±2 14±2 
    GIKCon 5±1 4±1 14±4* 16±4* 16±5* 17±4* 
    GIK300 6±1 6±1 13±2* 14±2* 13±2* 14±2* 
    GIK600 7±1 7±2 20±4* 13±2 11±2 10±2 
    GIK reperfusion 8±1 7±1 12±2* 13±3* 13±3* 13±2* 
    GIK600 reperfusion 8±1 7±2 14±3* 17±2* 12±2 11±2 
    Glb + GIK reperfusion 8±2 6±2 12±3 14±3* 16±3* 14±4* 
    Hyp + GIK reperfusion 8±1 8±1 17±1* 15±3* 11±1 12±2 
    DM + GIK reperfusion 5±1 5±1 7±1 8±1 9±1* 10±1* 
+dP/dtmax, mmHg/s 
      
    Con 2,000±160 2,100±150 1,640±160* 1,400±80* 1,430±70* 1,370±80* 
    GIKCon 1,940±110 2,060±180 1,350±90* 1,330±90* 1,440±160* 1,270±90* 
    GIK300 1,680±60 2,110±170* 1,420±70 1,350±100 1,410±120 1,540±150 
    GIK600 1,850±180 2,400±170* 1,570±130 1,700±130 1,530±130 1,520±30 
    GIK reperfusion 1,730±120 1,770±80 1,600±130 1,640±130 1,550±130 1,420±130* 
    GIK600 reperfusion 1,810±90 1,860±160 1,470±120* 1,720±140 1,830±80 1,690±120 
    Glb + GIK reperfusion 1,880±120 1,880±220 1,590±110 1,640±80 1,630±120 1,560±80 
    Hyp + GIK reperfusion 1,890±90 2,430±110* 2,000±90 1,760±100 1,670±110* 1,850±180 
    DM + GIK reperfusion 2,020±140 2,040±80 1,660±60* 1,620±140* 1,550±100* 1,440±80* 
Values are means ± SE. CAO, coronary artery occlusion; Con, control; GIK, glucose-insulin-potassium; Glb, glyburide; Hyp, hyperglycemia; DM, diabetes 
mellitus; HR, heart rate; MAP, mean arterial pressure; LVSP and LVEDP, left ventricular systolic and end-diastolic pressures, respectively; +dP/dtmax, 
maximum rate of increase of LV pressure. 
*P < 0.05, significantly different from baseline. 
 
BG and plasma insulin concentrations. 
Chemically induced DM significantly (P < 0.05) increased BG (Table 2) under baseline conditions (339 ± 21 mg/dl) 
compared with control (88 ± 66 mg/dl) dogs and BG remained elevated throughout the experiment. BG was 
unchanged in the GIKCon and GIK reperfusion groups. BG was increased during administration of supplemental 
intravenous dextrose. Plasma insulin concentrations were decreased in diabetic (2 ± 1 μU/ml) compared with 
control (11 ± 1 μU/ml) dogs. GIK administered before ischemia (GIKCon) or before reperfusion (GIK reperfusion) 
increased insulin concentration from 12 ± 3 and 10 ± 1 at baseline to 62 ± 12 and 79 ± 8 μU/ml, respectively, 
after 3 h of reperfusion. The magnitude of increase in the concentration of insulin during experimentation was 
dependent on the severity of hyperglycemia (e.g., insulin concentration increased to 542 ± 129 and 711 ± 145 
μU/ml after 3 h of reperfusion in the GIK600 and Hyp+GIK groups, respectively). 
Table 2. Blood glucose, plasma insulin, and systemic potassium concentrations 
  




Baseline Intervention 30-min CAO 1 3 
Blood glucose concentration, mg/dl 
     
    Con 88±6 86±8 93±10 101±18 98±13 
    GIKCon 74±5 86±5 89±9 74±2 78±7 
    GIK300 86±4 313±27*† 332±16*† 332±20*† 344±22*† 
    GIK600 66±7 580±11*† 595±4*† 580±13*† 600±10*† 
    GIK reperfusion 81±5 78±7 71±8 89±12 78±7 
    GIK600 reperfusion 84±5 76±5 78±3 569±25*† 579±20*† 
    Glb + GIK reperfusion 86±4 90±8 99±7 79±4 96±10 
    Hyp + GIK reperfusion 94±4 561±8*† 585±7*† 564±36*† 579±10*† 
    DM + GIK reperfusion 339±21† 324±23† 294±23† 419±30† 411±42† 
Insulin, μU/ml      
    Con 11±1 10±2 9±2 9±3 6±1 
    GIKCon 12±3 51±6*† 67±9*† 56±5*† 62±12*† 
    GIK300 21±11 181±21*† 195±37*† 279±66*† 356±78*† 
    GIK600 11±2 195±22*† 357±90*† 417±81*† 542±129*† 
    GIK reperfusion 10±1 9±1 15±7 89±15*† 79±8*† 
    GIK600 reperfusion 17±4 10±2 11±1 295±42*† 258±92*† 
    Glb + GIK reperfusion 13±3 58±12 70±18† 209±37*† 248±55*† 
    Hyp + GIK reperfusion 12±3 95±20† 156±30† 379±71*† 711±145*† 
    DM + GIK reperfusion 2±1† 1±0† 2±0† 63±14*† 64±6*† 
Values are means ± SE. 
*P < 0.05, significantly different from baseline; 
†P < 0.05, significantly different from the respective value in control experiments. 
 
Myocardial IS. 
There were no differences in LV AAR (data not shown) or coronary collateral blood flow (Table 3) between 
groups. IS was 29 ± 2% (n = 7) of AAR in control experiments (Fig. 2). GIK significantly decreased IS when 
administered at reperfusion, and this action was independent of BG [13 ± 2 (n = 7) and 12 ± 2% (n = 7) of AAR; 
BG = 80 or 600 mg/dl, respectively]. The protective effects of GIK were abolished in dogs pretreated with 
glyburide (30 ± 4%; n = 8). The salutary action of GIK was also eliminated in diabetic dogs (25 ± 3%; n = 7) and in 
dogs when hyperglycemia was present before ischemia (27 ± 4%; n = 7). GIK also failed to decrease IS when 
administered before ischemia (31 ± 3%; n = 7; BG = 80 mg/dl), and this effect was independent of BG [27 ± 2 (n = 
7) and 35 ± 3% (n = 7); BG = 300 or 600 mg/dl, respectively]. 
 
Fig. 2.Histograms illustrating myocardial infarct size expressed as a percentage of the left ventricular area at risk. 
Dogs were randomly subjected to saline (Con) or GIK administered before and during ischemia and reperfusion 
(GIKCon) or administered immediately before reperfusion. The effects of acute hyperglycemia to modulate the 
protection afforded by GIK were investigated in dogs receiving additional exogenous glucose to increase blood 
glucose to GIK300, GIK600, and Hyp + GIK. Other groups of dogs were subjected to experimental DM or received 
Glb. *P < 0.05, significantly different from Con. 
 
Table 3. Transmural myocardial perfusion in the ischemic region 
 
Baseline 30-min CAO 1-h Reperfusion 
Con 1.20±0.16 0.07±0.01* 1.74±0.12* 
GIKCon 1.29±0.22 0.05±0.03* 1.57±0.12 
GIK300 0.93±0.18 0.11±0.10* 1.67±0.19* 
GIK600 1.09±0.15 0.03±0.01* 1.73±0.25* 
GIK reperfusion 0.81±0.15 0.09±0.02* 2.32±0.15* 
GIK600 reperfusion 1.09±0.15 0.11±0.02* 1.47±0.25 
Glb + GIK reperfusion 0.77±0.17 0.10±0.04* 1.58±0.34* 
Hyp + GIK reperfusion 0.90±0.16 0.13±0.05* 1.99±0.35* 
DM + GIK reperfusion 0.73±0.10 0.10±0.02* 2.37±0.25* 
Values are means ± SE. The perfusion rate was measured in ml·min−1·g−1. 
*P < 0.05, significantly different from baseline. 
 
DISCUSSION 
Cardioprotective signaling during GIK. 
The mechanisms by which GIK reduces ischemic injury are incompletely understood. It has become increasingly 
clear that insulin-activated signaling pathways are central features responsible for GIK-induced cardioprotection 
(24). Insulin alone decreased IS in isolated rat hearts, and this beneficial effect was abolished by inhibitors of 
protein tyrosine kinase, phosphatidylinositol-3-kinase, and p70s6 kinase (16). Insulin also promoted nitric oxide 
production (10) and stimulated phosphorylation of Akt as well as its downstream targets p70s6 and apoptotic 
regulator BCL2 antagonist of cell death (BAD) (16). These results supported previous findings demonstrating that 
insulin markedly decreased apoptosis by activating protein tyrosine kinase and phosphatidylinositol-3-kinase in a 
myocyte model of simulated ischemia and reoxygenation (10, 15). The beneficial effects of insulin contrast with 
the effects of hyperglycemia. Hyperglycemia has been shown to promote apoptotic myocyte death by increased 
production of angiotensin II with subsequent activation of p53 and p38 mitogen-activated protein kinases (9). 
Recent evidence has also suggested a potential link between insulin signaling and KATP channel activation. 
KATP channels are critical mediators of ischemic preconditioning, a phenomenon responsible for powerful 
protection against myocardial infarction (11) and apoptosis (1). KATP channel activity is modulated by several 
intracellular kinases, including protein kinase C, protein tyrosine kinase, mitogen-activated protein kinases 
(5, 14), and phosphatidylinositol-3-kinase (30). Insulin has also been shown to regulate KATP channel activity 
(27, 29) by increasing the open-state probability of the channel and by decreasing channel sensitivity to ATP 
(28). Thus we hypothesized that insulin, administered as a component of GIK, produces cardioprotection by 
enhancing the activity of KATP channels. We further hypothesized that the presence of hyperglycemia negatively 
influences this process (17, 19, 21). 
GIK requires KATP activation. 
The present results demonstrate for the first time that KATP channels mediate GIK-induced myocardial 
protection. The findings indicate that the nonselective KATP channel antagonist glyburide abolishes salvage of 
ischemic and reperfused myocardium by GIK. Glyburide blocks mitochondrial and sarcolemmal KATP channels 
that have both been identified to play roles during ischemic preconditioning, although the relative importance 
of each subcellular location of the channel remains somewhat controversial (12). The present results contrast 
with the findings of a previous report (4), suggesting that the selective mitochondrial KATP channel antagonist 5-
hydroxydecanoate did not alter reductions in IS produced by a 5-min infusion of insulin 10 min before global 
ischemia in isolated rabbit hearts. Taken together, the present and previous data may implicate a role for the 
sarcolemmal KATP channel during cardioprotection with GIK. However, it is also possible that in the study of 
Baines et al. (4), 5-hydroxydecanoate administered during ischemia alone failed to block the beneficial effects of 
insulin because mitochondrial KATP channel blockade was not sustained throughout ischemia and reperfusion. 
The models chosen to evaluate the role of KATP channels during cardioprotection with GIK could also have 
influenced the results. We used intact, blood-perfused hearts with regional ischemia and reperfusion in 
anesthetized dogs, whereas Baines et al. (4) studied GIK in crystalloid perfused, globally ischemic, and 
reperfused isolated rabbit hearts. 
Hyperglycemia modulates GIK. 
The protective effects of GIK administered immediately before reperfusion occurred independent of BG during 
the reperfusion period as GIK was equally protective (IS = 13 ± 2 and 12 ± 2% of AAR) in the presence of 
sevenfold differences in BG (78 ± 7 and 579 ± 20 mg/dl, respectively). The present findings support previous 
observations in rats demonstrating that GIK or insulin alone administered immediately before reperfusion 
reduced IS, but glucose or potassium alone did not (10). The beneficial effects of insulin also persisted when 
pyruvate was substituted for glucose in this model, suggesting that substrate-specific metabolism may not be 
responsible for insulin-dependent cardioprotection (16). Interestingly, our results demonstrate that the 
presence of acute or chronic hyperglycemia before ischemia completely abolished the protective effects of GIK 
on reperfusion. The mechanism for this effect is not entirely clear but may involve adverse modulation of 
KATP channels by glucose. We (17) have shown that acute hyperglycemia or DM impairs activation of 
mitochondrial KATP channels, and this action is dependent on both the severity of hyperglycemia and the dose of 
KATP channel agonist. Acute and chronic hyperglycemia blocks ischemic preconditioning (17, 19) and produces 
dose-related increases in myocardial IS (17). In contrast to our earlier findings, we did not observe 
hyperglycemia-induced increases in IS in the present study when exogenous insulin was also administered. 
Although IS was not reduced by insulin in the presence of preischemic moderate or severe hyperglycemia, 
insulin may have mitigated the deleterious effects of hyperglycemia that might otherwise have increased the 
extent of myocardial ischemic injury. The previous and present results support the contention that glucose, a 
known regulator of pancreatic KATP channels (2), impairs activation of myocardial KATP channels. Increasing 
glucose concentration within a physiological range from 3 to 6.5 mM is sufficient to close KATP channels within 1–
3 min in pancreatic islet cells (23). This effect occurs concomitantly with increases in ATP concentration 
generated by oxidative substrate metabolism. Although the effects of glucose to regulate mitochondrial 
KATP channels have not been specifically investigated, it is likely that ATP generated from glucose metabolism 
also regulates channels in this organelle. Activation of KATP channels during ischemia appears to be required to 
elicit insulin-dependent cardioprotection on reperfusion. The finding that hyperglycemia, when present only 
during reperfusion, does not attenuate GIK cardioprotection was somewhat surprising and suggests that 
opening of KATP channels during ischemia may serve as an initial trigger for an effector that is subsequently 
modulated by insulin in a glucose-independent fashion. Candidates for such an effector may include mitogen-
activated protein kinases, other downstream kinases, or nitric oxide, all components of signaling pathways that 
have previously been shown to be modulated by insulin or KATP channels (10, 12). 
Beneficial effects of GIK occur at reperfusion. 
Clinical and experimental evidence indicates that the protective effects of insulin (as a component of GIK) occur 
predominantly during reperfusion (6, 10, 15, 16). The current results support this contention and demonstrate 
that GIK does not alter IS when administered before and during ischemia but substantially decreases injury 
when given immediately before reperfusion. The efficacy of GIK may be modulated under these conditions 
because of glucose-impaired KATP channel activation or due to metabolic effects of insulin and glucose. For 
example, preischemic glycogen depletion improves metabolic and contractile recovery in preconditioned rat 
hearts, and this effect may be related to decreased proton production from a reduction in hydrolysis of 
glycogen-derived ATP (25). Conversely, it has been suggested that administration of insulin and glucose before 
ischemia may increase glycogen stores and paradoxically increase the extent of ischemic damage, thus 
precluding any beneficial effect of insulin at reperfusion (16). The hypothesis that glycogen depletion is 
beneficial before ischemia and reperfusion is not supported by other evidence in the literature, however. 
Resynthesis of glycogen on reperfusion was correlated with the return of contractile function in isolated rat 
hearts subjected to global ischemia and reperfusion (7). Nonetheless, it was not our intention to characterize 
the complex metabolic effects of GIK but to explore the interrelationships among insulin, glucose, and 
KATP channels as modulators of ischemia and reperfusion injury during GIK. 
Limitations and conclusions. 
The present results should be interpreted within the constraints of several potential limitations. The LV AAR for 
infarction and coronary collateral blood flow, important determinants of the extent of infarction, were similar 
between groups and do not account for the observed results. The dose of glyburide used in the present 
investigation did not affect IS in a previous study (18). The dose of GIK was based on the regimen demonstrated 
to be most efficacious in the Estudios Cardiologicos Latinoamerica GIK pilot clinical trial (6). Hyperglycemia 
produced by administration of dextrose before ischemia caused transient increases in LV +dP/dtmax, an index of 
global myocardial contractility that is a major determinant of myocardial oxygen consumption. The increase in 
LV +dP/dtmax, in hyperglycemic dogs before ischemia suggests that ischemic burden may have been greater in 
these experimental groups. However, there were no differences in LV +dP/dtmax among groups, and it is unlikely 
that differences in the determinants of myocardial oxygen consumption among groups were solely responsible 
for the observed findings. Nevertheless, myocardial oxygen consumption was not directly measured in the 
current investigation. 
In summary, the present results confirm that GIK reduces myocardial IS when administered immediately before 
reperfusion in a canine model of prolonged coronary occlusion and reperfusion. This beneficial effect is 
dependent on opening of KATP channels during the ischemic period and is blocked by acute or chronic DM 
hyperglycemia before ischemia. The results reaffirm the temporal dependence of GIK administration and 
demonstrate for the first time that KATP channels mediate GIK-induced cardioprotection in vivo. 
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